Evolution of the Antidepressant Prescribing in Alzheimer’s Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer’s Disease (BNA)
Affiliations: [a] EA Cobtek, University of Nice Sophia-Antipolis, Nice, France | [b] Research Memory Centre, Nice University Hospital, Nice, France | [c] Department of Public Health, L’Archet Hospital, Nice University Hospital, Nice, France
Correspondence:
[*]
Correspondence to: Renaud David, Research Memory Centre, Nice University Hospital, 10 rue Molière, 06100 Nice, France. Tel.: +33 492034770; E-mail: david.r@chu-nice.fr.
Abstract: Background: Safety warnings from health authorities are currently intended to limit the use of psychotropic agents in dementia-related conditions. Evidence concerning the use of antidepressants in dementia is, however, scarce and contradictory. Objective: To evaluate antidepressant use among individuals with Alzheimer’s disease (AD) and related disorders in the French population between 2010 and 2014. Method: Antidepressant prescriptions in individuals with AD, mixed dementia (MD), and vascular dementia (VaD) in the French National Alzheimer Database between 2010 and 2014 were analyzed (N = 199,544). Results: Multivariate analysis showed an annual significant increase (p < 0.001) in the prescription rate of antidepressants from 26% (2010) to 31% (2014), and identified female gender, younger age, higher education, living in long-term facilities, more severe cognitive decline, and presence of vascular signs (VaD and MD) as associated factors for antidepressant prescribing. Conclusion: The annual increase of antidepressant prescribing among individuals with AD, MD, and VaD in French specialized settings may be partially related to the lack of current valuable medications for dementia-related behavioral symptoms.
